GT Biopharma Inc.

GTBP | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.18

$0 (0.00%)

At close: Sep 22, 2026, 4:00 PM ET

$7.20

+$0.02 (+0.25%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Sep 9, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $9.06M

1D Range

6.35 7.20

52W Range

4.91 34.25

Valuation (TTM)

PE -0.07

PB 2.54

EV/EBITDA -0.20

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target N/A

Cash Flow

FCF Yield -159.2%

SBC Adj. FCF Yield -169.2%

SBC Impact -6.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 32.9% | 32.1%

FCF 3Y | 5Y -11.1% | 3.1%

Returns

ROA -381.5%

ROE -443.1%

ROIC -457.8%

Financial Health

Net Cash

$4.96M

Current Ratio 2.61

Interest Coverage -128.64

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE...

Sector Healthcare

Industry Biotechnology

Employees 1

IPO Date Mar 26, 2018

Website www.gtbiopharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.